Genomic Valley Biotech Ltd Financial Ratios
GVBL · Healthcare · Current price ₹32.59
P/E ratio
325.9x
P/B ratio
2.5x
ROE
0.8%
ROCE
1.0%
Debt / Equity
0.00
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 325.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 2.5x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 0.8% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 1.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Genomic Valley Biotech Ltd's latest numbers.
Genomic Valley Biotech Ltd profitability
Genomic Valley Biotech Ltd generates a return on equity of 0.8% and a return on capital employed of 1.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of 325.9x, Genomic Valley Biotech Ltd is conservatively financed. Our overall business-quality score for the company is 2.7 / 10.
Understand the ratios
More on Genomic Valley Biotech Ltd
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.